Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
6274...Is that your Borg assigned number?
Correct. It's sick...Sickening. Turns governance into a joke. 5,000 more retail hooked, however. Thanks for the info, Les.
>>He says let me say to my 50,000 investors…. Well he’s not saying it to 50,000 viewers, he’s saying it to a hundred live at best.
It's the NWBO shuffle! If you've been around this one long enough you can see it coming from a mile away. You've now all been put on notice not to expect much until 2025.
Whenever I see him all I think is Smoke and Mirrors. "No news is good news" he says to 150,000,000 retail households. What a way to represent the alleged game changing disruptor biotech company. Eye rolls.
NOOOOOooooooo! LOL
Les got timed out. Can't make it up.
All is as LC says.
"Later in the fall"
...And, I remind you, in this day and age with fund raising is easier than ever and with social media moving good news at light speed, DCVAX-L should be in orbit by now with revenue IF it worked.
If it can only help "a few" L is exactly where it belongs with charity raised funds. Tax payers are not here to make biotech execs wealthy while starving real solutions of cash.
That is a remarkable story. The man has Balls of steel. Let's hope he's one of the few fortunate to respond to L.
>>Upon diagnosis, the pathologist informed us that they weren’t able to preserve enough of the tumor needed for the alternative treatment plan. We were then told that he had 3 months to live if he didn’t start chemotherapy and radiation treatment immediately.
My dad was adamant about the alternative treatment plan, so he took a chance and waited for the tumor to grow back in order to start the process all over again.
He had a second craniotomy on November 2nd, 2023 at the Jacksonville Mayo Clinic to extract the regrown tumor, which was a success. The doctors were able to preserve the tumor and send it off to NW Bio in the UK.
LOL...Yeah, BB was one of those fighting me on the notion of Acceptance all the way. That was some "Source in high places" he had. LOL. Note: No apologies.
Flip, remember this oldie but goodie? None of it ever really cleared up.
https://www.thestreet.com/investing/stocks/northwest-bio-executive-pleads-ignorance-about-clinical-trial-halt-stock-collapse-14072951
This one is my personal favorite. The disciples imagine one day they'll be on TV's "Biography" with the grand story of how he made it thanks to a cosmic connection to management.
"creation of generational wealth"
With the history, the silence, and ever stealthy increase in outstanding, I'm 99% certain the final rug pull will come with the share price leveling out at a nickel or so, leaving most Gen Z retail in shock. Seen it too many times to think otherwise.
Last week I put up a list, that nobody here bothered to address, of the five known NWBO "Big fish" investors. We know Woodford is long gone and Joan too, but the silence seems to suggest the others are gone, as well. ??
I can tell none of the disciples bought it because they're not using any of the reports figures here.
The GBM treatment field a now full of players with plenty of trials that'll cut into L's hypothetical UK business model. mRNA will almost certainly take center seat.
How about a buyout instead just to put retail out of their misery.
Sorry DanishDancer, but you don't get to use "Boiler room" to pretend it works to describe the skeptics. That one is 100% reserved for you and the pumpers.
Keep ignoring governance just like you should. Only confirms what we know about you. Yeah, the True-up...Meh. Eye rolls.
Is it Friday yet?
The longest they can drag this MHRA decision out is probably September.
When you first popped up I demanded disciples here have the company address your post. That never happened. All I need to know.
So dismissive. Here's how it more than likely goes:
-MHRA delays approval wants another trial and / or NICE refuses to cover. Or L stuck only in the UK.
-Already broke NWBO restructures or goes bankrupt
-Advent assumes the Sawston lease
-Advent absorbs Flaskworks
-Retail left with their pockets cut out.
DrugRunner says these are his scans but not sure what he's claiming??
https://www.thetransmitter.org/spectrum/new-atlases-chart-early-brain-growth-monkeys/
No. Retail has a non-U.S. "Facility" leased from the Chinese with all the manpower and technical knowhow provided by your CEO CFO Chair's private CDMO company. In return retail receives a lousy rent fee while paying office-warehousing lease costs to the Chinese along with taking some depreciation on equipment.
Is LP a mother?
This management crew runs things tighter than Los Alamos.
For only $3,250 you can get what regular biotech's give away to investors through cc's, presentations, and real analyst coverage. Eye rolls.
https://www.researchandmarkets.com/reports/5899244/dcvax-l-emerging-drug-insight-market-forecast
Always stunned me that NWBO never ran a solo L trial to prove it could stand alone.
>>Although current therapies provide 5-year overall survival of approximately 95%, patients who receive chemotherapy often have multiple relapses or progressions and worsening of functional decline, including visual impairment and hypothalamic dysfunction. In addition, radiation is associated with the risk of long-term neurologic and cognitive impairments and is therefore generally reserved for older patients after less toxic treatments have been exhausted.
https://www.nejm.org/doi/full/10.1056/NEJMoa2303815
Much of the "vaccine" for the Plll was produced by Cognate so they'll want to see the facility. Cognate was sold years ago by LP and others.
Calling that Dabrafenib / Trametinib article FUD should be an embarrassment to even the worst pumpers here. It provides a lot of information specific to what gets approved and why. You "Investors" have been 100% denied any L cost analysis figures thanks to zero analyst coverage and no quarterly cc's. You'd best get up to speed.
Blah blah blah...BioHarm. Nemesis is far more right than wrong on this.
>>Clinicians estimate that the BRAF V600E mutation affects 15-20% of paediatric low-grade gliomas and between five and 10% of paediatric high-grade gliomas. (1,2).
"I’m able to just take tablets twice a day and go to the hospital every few months, rather than be in hospital to have chemotherapy. I’ve been able to start secondary school with my friends and go to pretty much all my lessons. I’ve also been able to be at home, rather than staying in hospital for treatment, and carry on my hobbies such as majorette.”
https://www.thebraintumourcharity.org/news/treatment-news/dabrafenib-and-trametinib-approved-to-treat-childhood-gliomas/
Finally someone gets it!!!
Precisely. That's the first issue an analyst would tackle on a quarterly cc.
Hilarious you'd all ignore this one.
No. I've already posted where that wasn't the case. But continue to ignore the my posts and remain handicapped.
NIH just told us to expect cancer vaccines in the UK within five years so there's a way to go.
That might explain the 9 year 10 month delay.
"Children and teenagers with an aggressive form of brain cancer set to benefit after NICE recommends new life-extending drug combination treatment"
>>Clinical trials show the new treatment stalls the tumour growth in people with LGG for an average of more than two years – three times longer than current drugs.
“NICE is determined to get the best care to patients fast and ensure value for the taxpayer. This recommendation follows the licensing of both treatments for this type of cancer within the last three months.”
https://www.nice.org.uk/News/Article/children-and-teenagers-with-an-aggressive-form-of-brain-cancer-set-to-benefit-after-nice-recommends-new-life-extending-drug-combination-treatment
Agree. It's strange to me that over all these years the quarterlies never mentioned working closely with MHRA. Some here tried to fool us by saying MHRA approved the externals when they never did according to quarterly reports. Only when MHRA approved externals for PIP was it assumed MHRA were good with the old Plll changes. But that was never confirmed in writing or voiced by the voiceless CEO.
On another note, I find it odd that this new report has little to no comments on NICE.
You'll notice they still haven't started PIP trials. They had five years to consult with oncologist.
Impossible to take seriously especially with living cell science. Either MHRA isn't bothering because they know it's going nowhere or they finally accepted the application in March with some back and forth, IMO.
Didn't you hear? Advent will handle everything! And, while doing their own work with other non DC products. Had to be that way because LP took the whopping $1.5M grant from local government. Eye rolls.